Analogue-based drug discovery III /
Analogue-based drug discovery III /
Analogue-based drug discovery 3 Analog-based drug discovery III
edited by János Fischer, C. Robin Ganellin, David P. Rotella.
- 1 online resource (xviii, 385 pages) : illustrations, portraits
Includes bibliographical references and index.
General Aspects. Pioneer and Analogue Drugs / Competition in the Pharmaceutical Drug Development / Metabolic Stability and Analogue-Based Drug Discovery / Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / Selective Estrogen Receptor Modulators / Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / The Development of Cysteinyl Leukotriene Receptor Antagonists / Case Studies. The Discovery of Dabigatran Etexilate / The Discovery of Citalopram and Its Refinement to Escitalopram / Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / Novel Taxanes: Cabazitaxel Case Study / Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / A New-Generation Uric Acid Production Inhibitor: Febuxostat / Janos Fischer, C Robin Ganellin, David P Rotella -- Christian Tyrchan, Fabrizio Giordanetto -- Amit S Kalgutkar, Antonia F Stepan -- Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- A Ganesan -- Joseph A Jakubowski, Atsuhiro Sugidachi -- Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- Kazumi Kondo, Hidenori Ogawa -- Peter R Bernstein -- Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- Klaus P Bogeso, Connie Sanchez -- Helmut Buschmann -- Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- Ken Okamoto, Shiro Kondo, Takeshi Nishino.
"Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and--together with the previous volumes--constitutes the first systematic approach to drug analogue development"--Publisher's website.
9783527651085 352765108X 9783527651115 352765111X 9781299241206 1299241204
455370 MIL
Drug development.
MEDICAL--Drug Guides.
MEDICAL--Nursing--Pharmacology.
MEDICAL--Pharmacology.
MEDICAL--Pharmacy.
Drug development.
Electronic books.
Electronic books.
RM301.25 / .A53 2013
615.1/9
Includes bibliographical references and index.
General Aspects. Pioneer and Analogue Drugs / Competition in the Pharmaceutical Drug Development / Metabolic Stability and Analogue-Based Drug Discovery / Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / Selective Estrogen Receptor Modulators / Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / The Development of Cysteinyl Leukotriene Receptor Antagonists / Case Studies. The Discovery of Dabigatran Etexilate / The Discovery of Citalopram and Its Refinement to Escitalopram / Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / Novel Taxanes: Cabazitaxel Case Study / Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / A New-Generation Uric Acid Production Inhibitor: Febuxostat / Janos Fischer, C Robin Ganellin, David P Rotella -- Christian Tyrchan, Fabrizio Giordanetto -- Amit S Kalgutkar, Antonia F Stepan -- Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- A Ganesan -- Joseph A Jakubowski, Atsuhiro Sugidachi -- Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- Kazumi Kondo, Hidenori Ogawa -- Peter R Bernstein -- Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- Klaus P Bogeso, Connie Sanchez -- Helmut Buschmann -- Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- Ken Okamoto, Shiro Kondo, Takeshi Nishino.
"Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and--together with the previous volumes--constitutes the first systematic approach to drug analogue development"--Publisher's website.
9783527651085 352765108X 9783527651115 352765111X 9781299241206 1299241204
455370 MIL
Drug development.
MEDICAL--Drug Guides.
MEDICAL--Nursing--Pharmacology.
MEDICAL--Pharmacology.
MEDICAL--Pharmacy.
Drug development.
Electronic books.
Electronic books.
RM301.25 / .A53 2013
615.1/9